Pacira Pharmaceuticals Inc (NASDAQ:PCRX)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $31.94, but opened at $30.67. Pacira Pharmaceuticals shares last traded at $29.97, with a volume of 958083 shares changing hands.
PCRX has been the subject of several research analyst reports. BidaskClub upgraded Pacira Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, December 29th. Leerink Swann started coverage on Pacira Pharmaceuticals in a research note on Tuesday, January 2nd. They set a “market perform” rating and a $46.00 price objective on the stock. Zacks Investment Research cut Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. JPMorgan Chase & Co. restated a “hold” rating on shares of Pacira Pharmaceuticals in a research note on Thursday, January 4th. Finally, Royal Bank of Canada set a $54.00 price objective on Pacira Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, January 4th. Three analysts have rated the stock with a sell rating, twelve have given a hold rating and eight have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $44.82.
The company has a current ratio of 6.96, a quick ratio of 6.22 and a debt-to-equity ratio of 0.99. The stock has a market cap of $1,257.99, a P/E ratio of -27.50 and a beta of 1.95.
Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings results on Wednesday, February 28th. The company reported $0.38 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.46. Pacira Pharmaceuticals had a negative return on equity of 8.55% and a negative net margin of 14.87%. The business had revenue of $79.08 million for the quarter, compared to analyst estimates of $79.06 million. During the same quarter in the previous year, the firm earned $0.09 EPS. Pacira Pharmaceuticals’s quarterly revenue was up 8.5% on a year-over-year basis. sell-side analysts expect that Pacira Pharmaceuticals Inc will post -0.58 EPS for the current year.
In other news, CEO David M. Stack sold 28,885 shares of the stock in a transaction that occurred on Wednesday, January 10th. The stock was sold at an average price of $40.19, for a total transaction of $1,160,888.15. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 6.60% of the stock is owned by corporate insiders.
A number of large investors have recently modified their holdings of PCRX. Millennium Management LLC acquired a new stake in Pacira Pharmaceuticals during the fourth quarter worth approximately $24,644,000. Stonepine Capital Management LLC bought a new position in Pacira Pharmaceuticals during the 3rd quarter worth $14,089,000. Epoch Investment Partners Inc. raised its position in Pacira Pharmaceuticals by 195.7% during the 3rd quarter. Epoch Investment Partners Inc. now owns 535,999 shares of the company’s stock worth $20,127,000 after purchasing an additional 354,728 shares during the last quarter. Consonance Capital Management LP raised its position in Pacira Pharmaceuticals by 16.1% during the 4th quarter. Consonance Capital Management LP now owns 1,602,334 shares of the company’s stock worth $73,147,000 after purchasing an additional 222,200 shares during the last quarter. Finally, HealthCor Management L.P. raised its position in shares of Pacira Pharmaceuticals by 8.6% in the 4th quarter. HealthCor Management L.P. now owns 2,800,000 shares of the company’s stock worth $127,820,000 after acquiring an additional 221,960 shares in the last quarter.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.